About The Study: In this disproportionality study of an adverse drug reaction database, researchers identified a disproportionality signal of suicidal ideation with semaglutide, but not for liraglutide, particularly among patients with co-reported antidepressant use, a proxy for affective disorders (a notable exclusion criteria of premarketing clinical trials). A detected signal of semaglutide-associated suicidal ideation warrants urgent clarification.
About The Study: In this disproportionality study of an adverse drug reaction database, researchers identified a disproportionality signal of suicidal ideation with semaglutide, but not for liraglutide, particularly among patients with co-reported antidepressant use, a proxy for affective disorders (a notable exclusion criteria of premarketing clinical trials). A detected signal of semaglutide-associated suicidal ideation warrants urgent clarification.
Corresponding Author: To contact the corresponding author, Georgios Schoretsanitis, MD, PhD, email george.schor@gmail.com.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jamanetworkopen.2024.23385)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
Journal
JAMA Network Open
